Correlation of Morphological Appearance of Peritoneal Lesions at Laparotomy and Disease at Pathological Assessment in Patients Undergoing Cytoreductive Surgery for Peritoneal Malignancy: Results of Phase I of the PRECINCT Study in 707 Patients.

Cytoreductive surgery Morphology of peritoneal lesions Peritoneal cancer index Peritoneal metastases Peritoneal surface malignancy Surgical PCI

Journal

Annals of surgical oncology

ISSN: 1534-4681

Titre abrégé: Ann Surg Oncol

Pays: United States

ID NLM: 9420840

Informations de publication

Date de publication:
26 Aug 2024

Historique:

received: 23 01 2024

accepted: 01 08 2024

medline: 27 8 2024

pubmed: 27 8 2024

entrez: 26 8 2024

Statut: aheadofprint

Résumé

The PRECINCT (Pattern of peritoneal dissemination and REsponse to systemic Chemotherapy IN Common and uncommon peritoneal Tumors) is a prospective, multicenter, observational study. This report from phase I of PRECINCT outlines variations in recording the surgical peritoneal cancer index (sPCI) at experienced peritoneal malignancy centers and the incidence of pathologically confirmed disease in morphologically different peritoneal lesions (PL). The sPCI was recorded in a prespecified format that included the morphological appearance of PL. Six prespecified morphological terms were provided. The surgical and pathological findings were compared. From September 2020 to December 2021, 707 patients were enrolled at 10 centers. The morphological details are routinely recorded at two centers, structure bearing the largest nodule, and exact size of the largest tumor deposit in each region at four centers each. The most common morphological terms used were normal peritoneum in 3091 (45.3%), tumor nodules in 2607 (38.2%) and confluent disease in 786 (11.5%) regions. The incidence of pathologically confirmed disease was significantly higher in 'tumor nodules' with a lesion score of 2/3 compared with a lesion score of 1 (63.1% vs. 31.5%; p < 0.001). In patients receiving neoadjuvant chemotherapy, the incidence of pathologically confirmed disease did not differ significantly from those undergoing upfront surgery [751 (47.7%) and 532 (51.4%) respectively; p = 0.069]. The sPCI was recorded with heterogeneity at different centers. The incidence of pathologically confirmed disease was 49.2% in 'tumor nodules'. Frozen section could be used more liberally for these lesions to aid clinical decisions. A large-scale study involving pictorial depiction of different morphological appearances and correlation with pathological findings is indicated.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

The sPCI was recorded in a prespecified format that included the morphological appearance of PL. Six prespecified morphological terms were provided. The surgical and pathological findings were compared.

RESULTS RESULTS

From September 2020 to December 2021, 707 patients were enrolled at 10 centers. The morphological details are routinely recorded at two centers, structure bearing the largest nodule, and exact size of the largest tumor deposit in each region at four centers each. The most common morphological terms used were normal peritoneum in 3091 (45.3%), tumor nodules in 2607 (38.2%) and confluent disease in 786 (11.5%) regions. The incidence of pathologically confirmed disease was significantly higher in 'tumor nodules' with a lesion score of 2/3 compared with a lesion score of 1 (63.1% vs. 31.5%; p < 0.001). In patients receiving neoadjuvant chemotherapy, the incidence of pathologically confirmed disease did not differ significantly from those undergoing upfront surgery [751 (47.7%) and 532 (51.4%) respectively; p = 0.069].

CONCLUSIONS CONCLUSIONS

The sPCI was recorded with heterogeneity at different centers. The incidence of pathologically confirmed disease was 49.2% in 'tumor nodules'. Frozen section could be used more liberally for these lesions to aid clinical decisions. A large-scale study involving pictorial depiction of different morphological appearances and correlation with pathological findings is indicated.

Identifiants

DOI: 10.1245/s10434-024-16035-9 PMID: 39187665

pubmed: 39187665

doi: 10.1245/s10434-024-16035-9

pii: 10.1245/s10434-024-16035-9

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23 .

doi: 10.1007/978-1-4613-1247-5_23 pubmed: 8849962

Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2023;73:49–71. https://doi.org/10.3322/caac.21749 .

doi: 10.3322/caac.21749 pubmed: 35969103

Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. Ann Surg Oncol. 2016;23(1):114–9. https://doi.org/10.1245/s10434-015-4627-8 .

doi: 10.1245/s10434-015-4627-8 pubmed: 26014158

Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468–73. https://doi.org/10.1245/s10434-015-4962-9 .

doi: 10.1245/s10434-015-4962-9 pubmed: 26572754

Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, Bereder JM, Arvieux C, Boschetti G, Glehen O; BIG RENAPE Group. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 2016 Jun;23(6):1971-9. https://doi.org/10.1245/s10434-015-5081-3 .

Jónsdóttir B, Lomnytska M, Poromaa IS, et al. The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer. Ann Surg Oncol. 2021;28:244–51. https://doi.org/10.1245/s10434-020-08649-6 .

doi: 10.1245/s10434-020-08649-6 pubmed: 32472412

Demey K, Wolthuis A, de Buck van Overstraeten A, Fieuws S, Vandecaveye V, Van Cutsem E, D'Hoore A. External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol. 2017 Nov;24(12):3604-3608. https://doi.org/10.1245/s10434-017-6042-9 .

Enblad M, Ghanipour L, Cashin PH. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34(8):1390–5. https://doi.org/10.1080/02656736.2018.1464668 .

doi: 10.1080/02656736.2018.1464668 pubmed: 29695209

Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4 .

doi: 10.1016/S1470-2045(20)30599-4 pubmed: 33476595

Yonemura Y, Prabhu A, Sako S, Ishibashi H, Mizumoto A, Takao N, Ichinose M, Motoi S, Liu Y, Nishihara K, et al. Long Term Survival after Cytoreductive Surgery Combined with Perioperative Chemotherapy in Gastric Cancer Patients with Peritoneal Metastasis. Cancers. 2020;12(1):116. https://doi.org/10.3390/cancers12010116 .

doi: 10.3390/cancers12010116 pubmed: 31906405 pmcid: 7016959

Bhatt A, Kammar P, Mehta S, Damodaran D, Zaveri S, Patel MD, Sinukumar S, et al. Chasing Rainbows? the Possibility of “Cure” in Patients with Colorectal Peritoneal Metastases Undergoing Cytoreductive Surgery and HIPEC: a Retrospective Study by INDEPSO. Indian J Surg Oncol. 2019;10(Suppl 1):49–56. https://doi.org/10.1007/s13193-019-00879-9 .

doi: 10.1007/s13193-019-00879-9 pubmed: 30886494 pmcid: 6397129

Salo SAS, Lantto E, Robinson E, Myllärniemi M, Laaksonen S, Salo JA, Rantanen T, Ilonen I. Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study. Sci Rep. 2020;10(1):13257. https://doi.org/10.1038/s41598-020-70044-8 .

doi: 10.1038/s41598-020-70044-8 pubmed: 32764701 pmcid: 7411064

Avesani G, Arshad M, Lu H, Fotopoulou C, Cannone F, Melotti R, Aboagye E, Rockall A. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. Radiol Med. 2020;125(8):770–6. https://doi.org/10.1007/s11547-020-01170-6 .

doi: 10.1007/s11547-020-01170-6 pubmed: 32239470

Bhatt A, Yonemura Y, Mehta S, Benzerdjeb N, Kammar P, Parikh L, et al. The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors. Ann Surg Oncol. 2020;27(8):2985–96. https://doi.org/10.1245/s10434-020-08234-x .

doi: 10.1245/s10434-020-08234-x pubmed: 32040698

de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Doukas M, Verhoef C, Burger JWA. The Accuracy of the Surgical Peritoneal Cancer Index in Patients with Peritoneal Metastases of Colorectal Cancer. Dig Surg. 2021;38(3):205–11. https://doi.org/10.1159/000513353 .

doi: 10.1159/000513353 pubmed: 33657551

Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128(2):229–32. https://doi.org/10.1016/j.ygyno.2012.11.007 .

doi: 10.1016/j.ygyno.2012.11.007 pubmed: 23142076

Costantini B, Rosati A, Vargiu V, Gallitelli V, Di Ilio C, Moroni R, et al. Visual Peritoneal Evaluation of Residual Disease After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Patients: The VIPER Study. Ann Surg Oncol. 2023;30(4):2319–28. https://doi.org/10.1245/s10434-022-12861-x .

doi: 10.1245/s10434-022-12861-x pubmed: 36745255

Bhatt A, Rousset P, Baratti D, et al. Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study BMJ Open 2021;11:e046819. https://doi.org/10.1136/bmjopen-2020-046819

Bhatt A, Yonemura Y, Benzerdjeb N, Mehta S, Mishra S, Parikh L, et al. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study. Eur J Surg Oncol. 2019;45(12):2398–404. https://doi.org/10.1016/j.ejso.2019.07.019 .

doi: 10.1016/j.ejso.2019.07.019 pubmed: 31337527

Villeneuve L, Thivolet A, Bakrin N, et al. A new Internet tool to report peritoneal malignancy extent. peritoneal malignancy stage evaluation (promise) application. Eur J Surg Oncol 2016;42:877–82. https://doi.org/10.1016/j.ejso.2016.03.015

Villeneuve L, Passot G, Glehen O, et al. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis. 2017;12:37. https://doi.org/10.1186/s13023-017-0571-y .

doi: 10.1186/s13023-017-0571-y pubmed: 28212684 pmcid: 5316145

Bhatt A, Rousset P, Benzerdjeb N, et al. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. Colorectal Dis. 2020;22:2123–32. https://doi.org/10.1111/codi.15368 .

doi: 10.1111/codi.15368 pubmed: 32940414

Schnelldorfer T, Castro J, Goldar-Najafi A, Liu L. Development of a Deep Learning System for Intra-Operative Identification of Cancer Metastases. Ann Surg. Epub 5 Apr 2024. https://doi.org/10.1097/SLA.0000000000006294 .

Boussedra S, Benoit L, Koual M, Bentivegna E, Nguyen-Xuan HT, Bats AS, et al. Fluorescence guided surgery to improve peritoneal cytoreduction in epithelial ovarian cancer: A systematic review of available data. Eur J Surg Oncol. 2022;48(6):1217–23. https://doi.org/10.1016/j.ejso.2022.02.022 .

doi: 10.1016/j.ejso.2022.02.022 pubmed: 35227555

El-Swaify ST, Laban M, Ali SH, et al. Can fluorescence-guided surgery improve optimal surgical treatment for ovarian cancer? A systematic scoping review of clinical studies. Int J Gynecol Cancer. 2023;33:549–61.

doi: 10.1136/ijgc-2022-003846 pubmed: 36707085

Paumgartner G, Probst P, Kraines R, Leevy CM. Kinetics of indocyanine green removal from the blood. Ann N Y Acad Sci. 1970170:134–147

Yonemura Y, Canbay E, Ishibashi H, Nishino E, Endou Y, Sako S, et al. 5-Aminolevulinic Acid Fluorescence in Detection of Peritoneal Metastases. Asian Pac J Cancer Prev. 2016;17(4):2271–5. https://doi.org/10.7314/apjcp.2016.17.4.2271 .

doi: 10.7314/apjcp.2016.17.4.2271 pubmed: 27221929

Hentzen JEKR, de Jongh SJ, Hemmer PHJ, van der Plas WY, van Dam GM, Kruijff S. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a narrative review. J Surg Oncol. 2018;118(2):332–43. https://doi.org/10.1002/jso.25106 .

doi: 10.1002/jso.25106 pubmed: 29938400 pmcid: 6174973

Yonemura Y, Kawamura T, Bandou E, et al. The natural history of free cancer cells in the peritoneal cavity. In: S Gonzalez-Moreno, editor., et al., Advances in peritoneal surface oncology. Berlin: Springer-Verlag, Berlin Heidelberg; 2007. p. 11–23.

doi: 10.1007/978-3-540-30760-0_2

Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chir. 2016;71(2):124–45.

pubmed: 26847729